Levothyroxine and lung cancer in females: the importance of oxidative stress

Reproductive Biology and Endocrinology

Annarosa Finco³  Martino Recchia¹  Gianni Belcaro⁴  Umberto Cornelli² 

[1] University of Lugano, Lugano, Switzerland;Loyola University School of Medicine, Chicago, USA;Cor Con International-Ox Res Dept, Parma(PR), Italy;University of Chieti, Chieti, Italy

关键词: Dysthyroidism;    Lung cancer;    Oxidative stress;    Smoking;    Levothyroxine;   

Others  :  810942
DOI  :  10.1186/1477-7827-11-75

 received in 2013-04-19, accepted in 2013-07-24,  发布年份 2013

【 摘 要 】

Background

Levothyroxine (LT₄) treatment can lead to iatrogenic hyperthyroidism and oxidative stress that can cause patient discomfort. Oxidative stress is also recognized as one of the causes of chronic diseases and cancer.

Methods

The prevalence of breast, colorectal, gastric and lung cancer in 18 Italian Regions during 2010 was correlated with the sales of LT₄ in 2009. The cancer prevalence was analyzed in women aged 30–84. This age range corresponds to more than 80% of the consumers of the drug and to about 99% of all malignant cancers. The correlation between sales of LT₄ and cancers was determined with the technique of Density Ellipses. The age and smoking contribution for lung cancer was determined with the Sequential test.

Results

No significant correlation was seen between LT₄ sales and breast, colorectal and gastric cancers. A significant correlation was instead found for lung cancer (p < 0.05) corrected for smoking and age.

Conclusions

LT₄ consumption in Italy is about 0.7 boxes/women/year. There is a correlation between lung cancer and LT₄ treatment and oxidative stress caused by LT₄ supplementation can be one of the causes. Although we cannot exclude that dysthyroidism needing LT₄ supplementation might be the ground for lung cancer itself and measuring oxidative stress could be helpful in avoiding excessive use of the drug.

【 授权许可】

   
2013 Cornelli et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Hennessey JV, Malabanan AO, Haugen BR, Levy EG: Adverse effect reporting in patients treated with levothyroxine: results of the pharmacovigilance task force survey of the American Thyroid Association, American Association of Clinical Endocrinologists and the Endocrine Society. Endocr Pract 2010, 16:357-370.
• [2]Cornelli U, Belcaro G, Ledda A, Feragalli B: Oxidative stress following administration of levothyroxine in subjects suffering from primary hypothyroidism. Pan Med 2011, 35:1-4.
• [3]Cornelli U, Belcaro G, Ledda A, Feragalli B: Activity of some physiological modulators in reducing the side effects of levothyroxine in patients suffering from primary hypothyroidism. Pan Med 2011, 35:5-9.
• [4]Cetinkaya A, Kurutas EB, Buyukbese MA, Kantarceken B, Bulbuloglu E: Levels of malondialdehyde and superoxide dismutase in subclinical hyperthyroidism. Med Inflamm 2005, 1:57-59.
• [5]Fernandez V, Tapia G, Varela P, Romanque P, Cartier-Ugarte D, Videla LA: Thyroid hormone-induced oxidative stress in rodents and humans: a comparative view and relation to redox regulation of gene expression. Comp Biochem Physiol C Toxicol Pharmacol 2006, 142:231-239.
• [6]Venditti P, Di Meo S: Thyroid hormone-induced oxidative stress. Cell Mol Life Sci 2006, 63:414-434.
• [7]Bencivenga S, Bartolone L, Pappalardo MA, Russo A, Lapa D, Giorgianni G, Saraceno G, Trimarchi F: Altered intestinal absorption of L-thyroxine caused by coffee. Thyroid 2008, 18:293-301.
• [8]Russell W, Harrison RF, Smith N, Darzy K, Shalet S, Weetman AP, Ross RJ: Free triiodothyronine has a distinct circadian rhythm that is delayed but parallels thyrotropin levels. J Clin Endocrinol Metab 2008, 93:2300-2306.
• [9]Wonnacott TH, Wonnacott RJ (Eds): Regression: a second course in statistics. Lund, Sweden: John Wiley and Sons; 1981.
• [10]Rossner P, Gammon MD, Terry MB, Agrawal M, Zhang FF, Teitelbaum SL, Eng SM, Gaudet MM, Neugut AI, Santella RM: Relationship between urinary 15-F2 t-isoprostane and 8-oxodeoxyguanosine levels and breast cancer. Cancer Epidemiol Biomarkers Prev 2006, 15:639-644.
• [11]Rennet G, Rennert HS, Pinchev M, Gruber SB: A case control study of levothyroxine and risk of colorectal cancer. J Natl Cancer Inst 2010, 102:568-572.
• [12]Farchi G, Mariotti S, Menotti A, Seccareccia F, Torsello S, Fidanza F: Diet and 20-y mortality in two rural population groups of middle-aged men in Italy. Am J Clin Nutr 1989, 50:1095-1103.
• [13]Filaire E, Massart A, Rouveix M, Portier H, Rosado F, Durand D: Effect of 6 weeks of n-3 fatty acids and antioxidant mixture on lipid peroxidation at rest and post-exercise. Eur J Appl Physiol 2011, 111:1829-1839.
• [14]Hercbergs AH, Ashur-Fabian O, Garfield D: Thyroid hormone and cancer: clinical studies of hypothyroidism in oncology. Curr Opin Endocrinol Diabetes Obes 2010, 17:432-436.
• [15]Meng R, Tang HY, Westfall J, London D, Cao JH, Mousa SA, Luidens M, Hercbergs A, Davis FB, Davis PJ, et al.: Crosstalk between integrin αvβ3 and estrogen receptor-α is involved in thyroid hormone-induced proliferation in human lung carcinoma cells. PLoSone 2011, 11:e27547.
• [16]Faber J, Poulsen S, Iversen P, Kirkegaard C: Thyroid hormone turnover in patients with small cell carcinoma of the lung. Acta Endocrinol 1988, 118:460-464.
• [17]Ratcliffe JG, Stack BH, Burt RW, Radcliffe WA, Spilg WG, Cuthbert J, Kennedy RS: Thyroid function in lung cancer. Brit Med J 1978, 1:210-212.
• [18]Wawrzynska L, Sakowicz A, Rudzinski P, Langfort R, Kurzyna M: The conversion to triiodothyronine in the lung: comparison of activity of type I iodotironine 5’ deiodinase in lung cancer with peripheral lung tissues. Monaldi Arch Chest Dis 2003, 59:140-145.
• [19]Venditti P, Di Stefano L, Di Meo S: Oxidative stress in cold induced hyperthyroid state. J Exp Biol 2010, 213:2899-2911.
• [20]Kinoshita S, Sone S, Yamashita T, Tsubura E, Ogura T: Effects of experimental hyper-and hypothyroidism on natural defense activities against Lewis lung carcinoma and its spontaneous pulmonary metastases in C57BL/6 mice. Tokushima J Exp Med 1991, 38:25-35.
• [21]van Doorn J, Roelfsema F, van der Heide D: Concentration of thyroxine and 3,5,3’-triiodotyronine in several rat tissue in vivo: the effect of hypothyroidism. Endocrinology 1985, 117:1201-1208.
• [22]Nanda N, Bobby Z, Hamide A: Oxidative stress and protein glycation in primary hypothyroidism. Male/Female difference. Clin Exp Med 2008, 8:101-108.
• [23]Erdemar H, Demirci H, Yaman H, Erbil MK, Yakar T, Sancak B, Elbeg S, Biberoğlu G, Yetkin I: The effect of hypothyroidism, hyperthyroidism, and their treatment on parameters of oxidative stress and antioxidant status. Clin Chem Lab Med 2008, 46:1004-1010.
• [24]Costantini F, Pierdomenico SD, De Cesare D, De Remigis P, Bucciarelli T, Bittolo-Bon G, Cazzolato G, Nubile G, Guagnano MT, Sensi S, et al.: Effect of thyroid function on LDL oxidation. Atheroscler Throm Vasc Biol 1998, 18:732-737.
• [25]Cornelli U, Belcaro G, Finco A: The oxidative stress balance measured in humans with different markers, following a single oral antioxidants supplementation or a diet poor of antioxidants. J Chem Dermatol Sci Appl 2011, 1:64-70.
• [26]Bϋchner FL, Bueno-de-Mesquita HB, Linseisen J, Boshuizen HC, Kiemeney LA, Ros MM, Overvad K, Hansen L, Tjonneland A, Raaschou-Nielsen O, et al.: Fruits and vegetables consumption and the risk of histological subtypes of lung cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control 2010, 21:357-371.
• [27]Epplein M, Franke AA, Cooney RV, Morris JS, Wilkens LR, Goodman MT, Murphy SP, Henderson BE, Kolonel LN, Le Marchand L: Association of plasma micronutrients levels and urinary isoprostane with risk of lung cancer: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 2009, 18:1962-1970.
• [28]Otto T, Fandrey J: Thyroid hormone induces hypoxia-inducible factor 1α gene expression through thyroid hormone receptor β/retinoid x receptor α-dependent activation of hepatic leukemia factor. Endocrinology 2008, 149:2241-2250.
• [29]Hofer T, Desbaillets I, Höpfl G, Wenger RH, Gassmann M: Characterization of HIFD-1 alpha overexpressing Hela cells and implication for gene therapy. Comp Biochem Physiol C Toxicol Pharmacol 2002, 133:475-481.
• [30]Wan J, Chai H, Yu Z, Ge W, Kang N, Xia W, Che Y: H1F-1α on angiogenic potential in human small cell carcinoma. Clin Cancer Res 2011, 30:77. BioMed Central Full Text
• [31]Cesarone MR, Belcaro G, Nicolaides AN, Incandela L, De Sanctis MT, Barsotti A: San Valentino epidemiologic project. Angiology 2000, 51:S65-S68.